Dr. Senthil Chinnakannan

Dr. Senthil Chinnakannan is a distinguished vaccine designer and molecular biologist, and co-founder of Infinitopes Precision Immunomics. He holds a PhD in Molecular Virology from the University of London and has spent his career at the forefront of vaccine innovation, contributing to the co-development of the University of Oxford's multi-antigen vaccines for Hepatitis B, Hepatitis C, Influenza, COVID-19, and cancer.

Prior to co-founding Infinitopes in 2021, Senthil had already invented and contributed to five vaccine patents for the University of Oxford, establishing himself as a world expert in multi-epitope vaccine design. His deep understanding of vector biology — the systems used to deliver vaccine antigens to the immune system — became central to Infinitopes' high-efficiency vector delivery platform.

As co-founder and VP Vector Design at Infinitopes, Senthil leads the development of the vector component of the company's cancer vaccine platform, which aims to induce industry-leading levels of durable T-cell immunity. His work is central to the advancement of ITOP1, Infinitopes' lead vaccine candidate entering Phase I/IIa clinical trials in oesophageal cancer in 2025.